Treatment Results of Adjuvant Chemotherapy after Radical Hysterectomy for Intermediate-Risk Stage IB-IIB Cervical Cancer

Objective: The objective is to evaluate the effectiveness of chemotherapyas postoperative adjuvant therapy for stage IB-IIB cervical cancer with intermediate-riskfactors. Methods: We retrospectively reviewed the medical records of 119 cervicalcancer patients with intermediate-risk factors treated with radicalhysterectomy and pelvic lymphadenectomy from December 1997 to September 2010.The intermediate-risk factors included bulky tumor (≥4 cm), lymphovascularspace invasion, and deep stromal invasion. Sixteen patients did not receiveadjuvant therapy (observation group); 73 were treated with chemotherapy (CTgroup); 30 were treated with adjuvant radiation therapy (RT group). Thesignificance of the clinical parameters, 3- and 5-year overall survival (OS)rates of each group, was analyzed. Results: The 3- and 5-year OS rates betweenthe observation group and adjuvant therapy group (CT plus RT groups) were notstatistically different (3-year OS: 100% and 94.4%, respectively; 5-year OS:100% and 92.3%, respectively; p u003e 0.05). The 3- and 5-year OS rates betweenthe CT group and RT group were also not statistically different (3-year OS:93.6% and 96.4%, respectively; 5-year OS: 80.7% and 96.4%, respectively; p Univariate andmultivariate analysis of survival indicated that different adjuvant therapieswere not independent prognostic indicators for IB-IIB cervical cancer patientswith intermediate-risk factors. Conclusions: CT may have equivalent therapeuticeffect as RT for stage IB-IIB cervical cancer patients with intermediate-riskfactors after radical surgery, and prospective randomized trial is needed to studythe effect of CT in these patients.